Histogenics closed its previously-announced US $30.0MM private placement of common stock, Series A Convertible Preferred Stock and warrants. Funds will support development of NeoCart® novel cartilage repair therapy, including completion of the ongoing Phase III clinical trial.
The transaction was led by new healthcare-dedicated institutional investors, with participation by some existing investors.
Enrollment in the Phase III clinical trial should complete in 2Q17, with topline data on its 1-year primary efficacy endpoint available by mid-2018. Over 50% of enrollment was complete by mid-1Q16.
Histogenics closed its previously-announced US $30.0MM private placement of common stock, Series A Convertible Preferred Stock and warrants. Funds will support development of NeoCart® novel cartilage repair therapy, including completion of the ongoing Phase III clinical trial.
The transaction was led by new healthcare-dedicated institutional...
Histogenics closed its previously-announced US $30.0MM private placement of common stock, Series A Convertible Preferred Stock and warrants. Funds will support development of NeoCart® novel cartilage repair therapy, including completion of the ongoing Phase III clinical trial.
The transaction was led by new healthcare-dedicated institutional investors, with participation by some existing investors.
Enrollment in the Phase III clinical trial should complete in 2Q17, with topline data on its 1-year primary efficacy endpoint available by mid-2018. Over 50% of enrollment was complete by mid-1Q16.
Our site uses cookies to allow easier access for Members and subscribers and to improve our site. You agree to our use of cookies by closing this message box or continuing to use our site.OkRead more
Copy to clipboard 
